

---

**SUBSTITUTE SENATE BILL 6404**

---

**State of Washington**

**66th Legislature**

**2020 Regular Session**

**By** Senate Health & Long Term Care (originally sponsored by Senators Frockt, O'Ban, Dhingra, Becker, Kuderer, Rivers, Lovelett, Wellman, Pedersen, Nguyen, Darneille, Hasegawa, McCoy, Wilson, C., Das, Conway, and Saldaña)

READ FIRST TIME 02/06/20.

1 AN ACT Relating to reducing barriers to patient care through  
2 appropriate use of prior authorization and adoption of appropriate  
3 use criteria; adding a new section to chapter 48.43 RCW; and adding a  
4 new section to chapter 70.250 RCW.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

6 NEW SECTION. **Sec. 1.** A new section is added to chapter 48.43  
7 RCW to read as follows:

8 (1) By October 1, 2020, and annually thereafter, for health plans  
9 issued by a carrier, the carrier shall report to the commissioner the  
10 following aggregated and deidentified data related to the carrier's  
11 prior authorization practices and experience for the prior plan year:

12 (a) Lists of the ten inpatient medical or surgical services,  
13 which may include mental health and substance use disorders:

14 (i) With the highest total volume of prior authorization requests  
15 during the previous plan year, including the total number of prior  
16 authorization requests for each service;

17 (ii) With the highest number of approved prior authorization  
18 requests during the previous plan year, including the total number of  
19 prior authorization requests for each service; and

20 (iii) With the highest number of prior authorization requests  
21 that were initially denied and then subsequently approved on appeal,

1 including the total number of prior authorization requests for each  
2 service;

3 (b) Lists of the ten outpatient medical or surgical services,  
4 which may include mental health and substance use disorders:

5 (i) With the highest total volume of prior authorization requests  
6 during the previous plan year, including the total number of prior  
7 authorization requests for each service;

8 (ii) With the highest number of approved prior authorization  
9 requests during the previous plan year, including the total number of  
10 prior authorization requests for each service; and

11 (iii) With the highest number of prior authorization requests  
12 that were initially denied and then subsequently approved on appeal,  
13 including the total number of prior authorization requests for each  
14 service;

15 (c) The average determination response time in hours for prior  
16 authorization requests to the plan with respect to each covered  
17 service listed in (a) and (b) of this subsection for each of the  
18 following categories:

19 (i) Urgent concurrent decisions;

20 (ii) Urgent preservice decisions;

21 (iii) Nonurgent preservice decisions; and

22 (iv) Postservice decisions.

23 (2) The commissioner shall provide the data collected under  
24 subsection (1) of this section to the prior authorization work group.

25 (3) The commissioner shall develop standardized reports of the  
26 aggregated and deidentified data submitted under subsection (1) of  
27 this section and make the reports available upon request to  
28 interested parties.

29 (4) The commissioner shall post recommendations from the prior  
30 authorization work group made under section 2 of this act on the  
31 commissioner's web site.

32 (5) The commissioner may adopt rules to implement this section.  
33 In adopting rules, the commissioner must consult stakeholders  
34 including carriers, health care practitioners, health care  
35 facilities, and patients.

36 (6) For the purpose of this section, "prior authorization" means  
37 a mandatory process that a carrier or its designated or contracted  
38 representative requires a provider or facility to follow before a  
39 service is delivered, to determine if a service is a benefit and  
40 meets the requirements for medical necessity, clinical

1 appropriateness, level of care, or effectiveness in relation to the  
2 applicable plan, including any term used by a carrier or its  
3 designated or contracted representative to describe this process.

4 NEW SECTION. **Sec. 2.** A new section is added to chapter 70.250  
5 RCW to read as follows:

6 (1)(a) The prior authorization work group is created to enhance  
7 the understanding and use of prior authorization in Washington state.  
8 The prior authorization work group must be hosted and staffed by the  
9 collaborative.

10 (b) By September 1, 2020, the governor shall appoint fifteen  
11 members of the prior authorization work group to be comprised of  
12 representatives from health care providers, hospitals, clinics,  
13 carriers, and the health care authority. All appointed  
14 representatives must be clinicians with at least fifty percent  
15 representing providers, hospitals, and clinics, and at least twenty-  
16 five percent representing carriers. The appointed members of the  
17 prior authorization work group shall select the work group chair.

18 (2)(a) By January 1, 2021, and annually thereafter, the prior  
19 authorization work group shall select and review not less than five  
20 medical or surgical services, which may include mental health and  
21 substance use disorder services, subject to prior authorization by  
22 insurance carriers. The prior authorization work group shall conduct  
23 its review and issue prior authorization recommendations by December  
24 31st of the year in which the review began.

25 (b) The prior authorization work group shall establish  
26 subcommittees to focus on specific services selected for review. Each  
27 subcommittee must be comprised of practicing clinicians with  
28 expertise relevant to the specific medical or surgical service  
29 selected for review. Each subcommittee must include at least two  
30 members of the specialty or subspecialty society most experienced  
31 with the service identified for review. Subcommittee members are not  
32 required to be members of the prior authorization work group. Each  
33 subcommittee shall make recommendations to the prior authorization  
34 work group related to the recommendations in subsection (3) of this  
35 section.

36 (c) In 2021 the prior authorization work group shall review, as  
37 one of the services selected, noninvasive cardiac diagnostic imaging  
38 procedures.

1 (d) The prior authorization work group shall consider the prior  
2 authorization data collected in section 1 of this act and shall  
3 select and prioritize services for review based on the following  
4 criteria:

5 (i) The volume of the service as indicated by prior authorization  
6 requests;

7 (ii) Indications based on medical literature that prior  
8 authorization is not appropriate for a service;

9 (iii) The potential for negative impact on patient care caused by  
10 prior authorization delays; and

11 (iv) Input from health care providers, health care facilities,  
12 insurance carriers, and health insurance purchasers.

13 (3) For each service identified in subsection (2) of this  
14 section, the prior authorization work group shall assess the  
15 following areas and make corresponding recommendations:

16 (a) Whether the utilization and approval patterns and medical  
17 literature justify the use of a prior authorization requirement for  
18 the service. If not, the prior authorization work group shall  
19 recommend no prior authorization be required for the service;

20 (b) Whether adoption of uniform appropriate use criteria or  
21 evidence-based criteria confirmed through a clinical decision support  
22 mechanism for the service in lieu of prior authorization is  
23 appropriate. If so, the prior authorization work group shall identify  
24 and select appropriate criteria for the service. The prior  
25 authorization work group shall consider the availability and cost of  
26 the clinical decision support mechanisms and possible alternative  
27 methods of validation in its recommendation. If the work group  
28 recommends the use of appropriate use criteria related to noninvasive  
29 cardiac diagnostic imaging procedures, the work group shall recommend  
30 adoption of appropriate use criteria developed by a federally  
31 qualified provider led entity pursuant to 42 C.F.R. 414.94 as it  
32 existed on February 1, 2020;

33 (c) Whether an appropriate federal policy or initiative exists  
34 for the service. Any recommendations by the prior authorization work  
35 group should align with criteria used for federal initiatives and  
36 approval mechanisms under the medicare program; and

37 (d) The prior authorization work group shall consider the  
38 services as provided to both adult and pediatric patients and when  
39 appropriate, provide separate recommendations regarding the service  
40 for adult and pediatric patients.

1 (4) The prior authorization work group shall review and make  
2 updates as necessary to the recommendations made pursuant to  
3 subsection (3) of this section based on evidence that a  
4 recommendation no longer reflects relevant evidence-based guidelines.

5 (5) Beginning December 1, 2021, the work group must annually  
6 report on its recommendations to the health care committees of the  
7 legislature.

8 (6) For purposes of this section:

9 (a) "Prior authorization" means a mandatory process that a  
10 carrier or its designated or contracted representative requires a  
11 provider or facility to follow before a service is delivered, to  
12 determine if a service is a benefit and meets requirements for  
13 medical necessity, clinical appropriateness, level of care, or  
14 effectiveness in relation to the applicable plan, including any term  
15 used by a carrier or its designated or contracted representative to  
16 describe this process.

17 (b) "Appropriate use criteria" means criteria developed or  
18 endorsed by a provider-led entity to assist health care practitioners  
19 in making the most appropriate treatment decision for a specific  
20 clinical condition for an individual. To the extent feasible, such  
21 criteria must be evidence-based.

22 (c) "Clinical decision support mechanism" means a tool for use by  
23 clinicians that communicates selected appropriate use criteria  
24 information to the user and assists clinicians in making the most  
25 appropriate treatment decision for a patient's specific clinical  
26 condition.

27 (d) "Provider-led entity" means a professional medical specialty  
28 society or organization.

--- END ---